Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, 89Zr-daratumumab, Dartumumab, PET/CT
Brief summary
Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.
Detailed description
This will be a phase II clinical trial to assess the potential clinical value of 89Zr-DFO-daratumumab immunoPET. 60 patients with multiple myeloma (MM) and a plan for daratumumab containing combination therapy will be enrolled. Prior to therapy, current standard of care (SoC), as well as a research 89Zr-DFO-daratumumab PET/CT, tests will be performed. Patients will then undergo standard of care therapy for myeloma as defined by a medical oncologist and SoC response assessments as defined by the International Myeloma Working Group (IMWG). Upon suspected complete response (CR) or completion of 12 cycles of therapy, a repeat research 89Zr-DFO-daratumumab PET/CT will be repeated and standard of care minimal residual disease (MRD) assessment will be performed. This design will determine how 89Zr-DFO-daratumumab immunoPET compares with current methods of measuring and localizing disease prior to therapy, if immunoPET can predict response to therapy, and how immunoPET compares with current methods of detecting MRD after therapy. The therapy in this trial is standard of care. The research component is the addition of a novel immunoPET imaging test before and after standard of care therapy, to determine if the novel imaging test adds value over current measures of myeloma disease burden.
Interventions
DRUG89Zr-daratumumab PET/CT
CD38-targeting imaging
Sponsors
Hoag Memorial Hospital Presbyterian
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Individual dose of 89Zr-DFO-daratumumab will be requested from Memorial Sloan Kettering Cancer Center and received at the Hoag Family Cancer Institute radiopharmacy for each individual 89Zr-DFO-daratumumab administration.
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female ≥ 21 years of age 2. Histologically/immunohistochemistry-confirmed CD38-positive multiple myeloma 3. At least one tumor lesion on CT, MRI, or FDG PET/CT within 90 days of protocol enrollment 4. ECOG performance status 0 to 2 5. Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
Exclusion criteria
1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. Life expectancy \< 12 months 3. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds. 4. History of anaphylactic reaction to humanized or human antibodies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 89Zr-daratumumab PET/CT for pre-treatment multiple myeloma imaging | up to 3 years | 89Zr-daratumumab PET/CT will be compared against standard of care laboratory and imaging measurements of multiple myeloma prior to therapy |
| 89Zr-daratumumab PET/CT for post-treatment multiple myeloma imaging | up to 3 years | 89Zr-daratumumab PET/CT will be compared against standard of care laboratory and imaging measurements of multiple myeloma following therapy |
| Prediction of response to therapy | up to 3 years | Determine if tumor uptake of 89Zr-daratumumab predicts response to therapy |
Countries
United States
Contacts
Primary ContactGary Ulaner, MD, PhD
Backup ContactBeth Thomsen, CNMT
Outcome results
None listed